Key takeaways
MRESVIA (RSV vaccine) and Arexvy (RSV vaccine) are both vaccines used to prevent illness caused by respiratory syncytial virus (RSV) in adults 60 years and older. They are similar in that they are both given as a single injection into the muscle and are not controlled medications. However, they differ in their composition and specific indications. MRESVIA is an mRNA vaccine, while Arexvy is a recombinant protein vaccine. MRESVIA is specifically for adults 60 and older, whereas Arexvy can also be given to adults 18 to 59 years old who are at higher risk for severe RSV illness. Both vaccines have common side effects like tiredness and muscle pain, but Arexvy has a noted risk of Guillain-Barré syndrome, a rare condition where the immune system attacks the nerves. Additionally, both can be given with other vaccines, but this might increase the chance of side effects.
